InvestorsObserver
×
News Home

Spruce Biosciences to Participate in the Jefferies Healthcare Conference

Wednesday, May 24, 2023 04:05 PM | Business Wire via QuoteMedia

Mentioned in this article

Spruce Biosciences to Participate in the Jefferies Healthcare Conference

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 9, 2023, at 9:30 a.m. ET.

Interested parties can access the live webcast here . An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @ Spruce_Bio , LinkedIn , Facebook and YouTube .

Media Contact
Will Zasadny
Evoke Canale
(619) 961-8848
will.zasadny@evokecanale.com
media@sprucebio.com

Investors
Xuan Yang
Solebury Strategic Communications
(415) 971-9412
xyang@soleburystrat.com
investors@sprucebio.com

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App